Researchers from California and New York reported a small molecule with activity against nonreplicating and drug-resistant Mycobacterium tuberculosis. The compound, which inhibits two biosynthetic enzymes, could be combined with existing TB drugs to shorten treatment duration and prevent the emergence of resistance.